News

Hosted on MSN8mon
Pfizer gets FDA approval for Hympavzi for hemophilia - MSN
Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia.The agency approved Hympavzi as a routine prophylaxis to prevent or reduce the ...
Medscape8mon
FDA Approves Pfizer's Hympavzi for Hemophilia A, B - Medscape
The US Food and Drug Administration (FDA) has approved Hympavzi (marstacimab, Pfizer) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years or older ...
Hosted on MSN8mon
FDA Approves Hympavzi for Hemophilia Treatment, Offering Novel Approach to Bleeding Disorder Management - MSN
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in patients aged ...
Nasdaq8mon
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors - Nasdaq
“HYMPAVZI is Pfizer’s second hemophilia treatment to receive FDA approval this year and is the latest meaningful scientific advancement in our more than 40-year commitment to improve care for ...
Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
Fierce Pharma10d
Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
Healio8mon
FDA approves Hympavzi for hemophilia A or B without inhibitors - Healio
The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia.The indication applies to routine prophylaxis to prevent or reduce frequency of bleeding episodes among ...
WebMD8mon
New Hemophilia Drug Helps Prevent Bleeding Episodes - WebMD
Preventive standard treatments averaged the equivalent of 7.85 episodes per year, compared to 5.08 per year with Hympavzi. The FDA called that rate with Hympavzi “similar” to the rate with ...
Benzinga.com8mon
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...
Seeking Alpha8mon
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors - Seeking Alpha
“HYMPAVZI is Pfizer’s second hemophilia treatment to receive FDA approval this year and is the latest meaningful scientific advancement in our more than 40-year commitment to improve care for ...
Pharm Exec8mon
FDA Approves Pfizer’s Hympavzi for Prophylaxis in Patients with Hemophilia A or B
The FDA has approved Pfizer’s Hympavzi (marstacimab-hncq) for routine prophylaxis (RP) in adults and adolescents over 12 years of age with hemophilia A or B without inhibitors. Hympavzi is now the ...
Seeking Alpha8mon
Pfizer gets FDA approval for Hympavzi for hemophilia
Pfizer added Hympavzi is the first FDA-approved once-weekly subcutaneous prophylactic treatment for hemophilia B and the first to be administered via a pre-filled pen or syringe for hemophilia A or B.